We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

DIASORIN

DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tes... read more Featured Products: More products

Download Mobile App




Automated Multiplexing Molecular Diagnostic Platform Revolutionizes Infectious Disease Diagnostics

By LabMedica International staff writers
Posted on 06 Mar 2024
Print article
Image: The LIAISON PLEX system has received US FDA 510(K) clearance (Photo courtesy of Diasorin)
Image: The LIAISON PLEX system has received US FDA 510(K) clearance (Photo courtesy of Diasorin)

A new fully automated multiplexing molecular diagnostic platform offers an innovative and cost-effective testing approach by allowing customization of tests along with the ability to process and pay for desired results, thus enabling laboratories to maximize testing efficiencies.

Diasorin’s (Saluggia, Italy) new LIAISON PLEX platform provides complete flexibility for the customization of syndromic panels and helps overcome the challenge of the “one size fits all" approach faced by clinical laboratory staff for infectious disease syndromic diagnostics. Custom panels enable adjustments in response to seasonal changes and updates in clinical guidelines, helping prevent unnecessary and costly over-testing - a common issue with fixed, broad syndromic panels currently in use. The user-friendly, fully automated sample-to-answer system offers a streamlined workflow and room-temperature stable consumables, simplifying storage and transport logistics. Additionally, it requires just two minutes of hands-on time per sample and can deliver results in less than two hours.

The LIAISON PLEX, originally named VERIGENE II by Luminex, is VERIGENE’s successor, which is already providing flexible solutions with its Respiratory Panel. The PLEX system takes the Flex Testing concept to a new level with full customization of its existing and upcoming panels and full automation. This minimizes sample preparation time and contamination risks for laboratory technicians. The improved flexibility and automation add value for patients, clinicians, and payers. Given its unique features and technology, LIAISON PLEX is expected to boost Diasorin's commercial strategy in the U.S. by focusing on the hospital segment, leveraging IDNs, teaching institutions, and medical centers.

The LIAISON PLEX Respiratory Flex Assay is capable of testing for 19 pathogens linked to respiratory infections, which include 14 viral and 5 bacterial targets from nasopharyngeal swabs. The platform's Flex testing technology is unique in that it allows laboratories to select and pay for only specific results based on the patient's clinical symptoms, as opposed to standard panel tests that process all results simultaneously. This Flex approach enhances clinical utility and can lead to better reimbursement rates, making it a more cost-effective option for patients. The application of such targeted panel testing aids in precise diagnosis and treatment, aligning with the goals of diagnostic stewardship. This leads to reduced unnecessary patient therapies and avoids the costs associated with over-testing. The LIAISON PLEX platform, along with its Respiratory Flex Assay, has gained 510(k) clearance from the U.S. Food and Drug Administration (FDA).

“The LIAISON PLEX and its Respiratory Panel will allow clinical laboratories and physicians to tailor tests to the needs of their patient population,” said Angelo Rago, President of Luminex. “The LIAISON PLEX is truly a laboratory's sample-to-customizable answer solution and we believe this will help address the growing demand for diagnostic stewardship, fiscal responsibility, and operational efficiency in clinical labs and healthcare systems throughout the U.S.”

“The clearance of the LIAISON PLEX along with its first panel marks a significant and strategic milestone for Diasorin after the Luminex acquisition, delivering to the market an innovative platform that is uniquely positioned in the growing multiplexing industry” added Carlo Rosa, CEO of Diasorin. “The flex technology exemplifies our forward-looking approach to diagnostic development, tackling the current limitations of the multiplexing market with a fully automated and customizable panel, and providing customers with the needed flexibility to adopt this technology in a cost-effective manner.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.